Skip to content
HowShorted

CytomX Therapeutics, Inc. short interest in 2019

In 2019, CytomX Therapeutics, Inc.'s disclosed short interest ran from 4.90% of shares outstanding on 15 Jan 2019 to 3.42% on 31 Dec 2019, a change of -1.48 percentage points. The year's high was 5.51% on 29 Mar 2019 and its low 3.42% on 31 Dec 2019, averaging 4.46% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.19 days on 31 Jan 2019. Full history: CytomX Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CytomX Therapeutics, Inc. in 2019

2019 in figures

Start of year
4.90% (15 Jan 2019)
End of year
3.42% (31 Dec 2019)
Change
-1.48 pp
High
5.51% (29 Mar 2019)
Low
3.42% (31 Dec 2019)
Average
4.46%
Highest days to cover
10.19 (31 Jan 2019)
SEC filings marked
8

Every report in 2019

CytomX Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20194.90%7.37
31 Jan 20195.23%10.19
15 Feb 20195.40%7.77
28 Feb 20194.53%2.2910-K filed, results (8-K)
15 Mar 20194.21%1.74
29 Mar 20195.51%5.12
15 Apr 20195.45%7.13
30 Apr 20195.06%5.52
15 May 20194.43%4.0410-Q filed, results (8-K)
31 May 20194.20%5.21
14 Jun 20194.09%6.49
28 Jun 20193.69%4.29
15 Jul 20194.03%4.88
31 Jul 20193.89%6.67
15 Aug 20193.88%4.9410-Q filed, results (8-K)
30 Aug 20194.00%7.70
13 Sep 20194.58%8.03
30 Sep 20194.03%6.68
15 Oct 20193.83%2.11
31 Oct 20194.34%3.37
15 Nov 20194.76%4.6610-Q filed, results (8-K)
29 Nov 20194.57%4.41
13 Dec 20195.12%6.03
31 Dec 20193.42%2.90

See also: CytomX Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.